{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:48:22Z","timestamp":1783190902999,"version":"3.54.6"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171503"],"award-info":[{"award-number":["82171503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871052"],"award-info":[{"award-number":["81871052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00714","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T19:41:36Z","timestamp":1754509296000},"page":"e00714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shared and unique therapeutic targets of KarXT and clozapine for schizophrenia treatment revealed by network pharmacology and molecular docking analyses: Implications for differential clinical responses"],"prefix":"10.1016","volume":"22","author":[{"given":"Chuanjun","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yachen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.neurot.2025.e00714_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.2019.11073","article-title":"Schizophrenia","volume":"322","author":"Borelli","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00714_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"National burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"9","author":"Global","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"10323","key":"10.1016\/j.neurot.2025.e00714_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00714_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"4 Suppl","key":"10.1016\/j.neurot.2025.e00714_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1359786810385490","article-title":"Suicide and schizophrenia: a systematic review of rates and risk factors","volume":"24","author":"Hor","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neurot.2025.e00714_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.schres.2022.10.019","article-title":"Factors and their weight in reducing life expectancy in schizophrenia","volume":"250","author":"Correll","year":"2022","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00714_bib7","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"10422","key":"10.1016\/j.neurot.2025.e00714_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00714_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","article-title":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","volume":"274","author":"Wright","year":"2024","journal-title":"Schizophr Res"},{"key":"10.1016\/j.neurot.2025.e00714_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front Psychiatr"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00714_bib12","article-title":"Cardiovascular risk for patients with and without schizophrenia","volume":"11","author":"Rossom","year":"2022","journal-title":"Schizoaffective Disorder, or Bipolar Disorder"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00714_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S2215-0366(24)00173-1","article-title":"Treatment paradigms for treatment-resistant schizophrenia","volume":"11","author":"Lim","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00714_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/YCO.0000000000000403","article-title":"Sudden death in schizophrenia","volume":"31","author":"Li","year":"2018","journal-title":"Curr Opin Psychiatr"},{"key":"10.1016\/j.neurot.2025.e00714_bib15","first-page":"1","article-title":"Genetic identification of undiagnosed benign ethnic neutropenia in patients receiving clozapine treatment","author":"Aziri","year":"2024","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00714_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00714_bib17","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1503\/jpn.240065","article-title":"Network pharmacology and molecular docking to explore mechanisms of clozapine-induced cardiac arrest","volume":"50","author":"Chen","year":"2025","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00714_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70206","article-title":"Clozapine induces agranulocytosis via inflammatory and hematopoietic cytokine induction of the JAK-STAT signaling pathway: evidence from network pharmacology and molecular docking","volume":"31","author":"Zhang","year":"2025","journal-title":"CNS Neurosci Ther"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.neurot.2025.e00714_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx374","article-title":"PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"10.1016\/j.neurot.2025.e00714_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2025.e00714_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baq020","article-title":"GeneCards version 3: the human gene integrator","volume":"2010","author":"Safran","year":"2010","journal-title":"Database"},{"issue":"Web Server issue","key":"10.1016\/j.neurot.2025.e00714_bib23","doi-asserted-by":"crossref","first-page":"W26","DOI":"10.1093\/nar\/gku477","article-title":"SuperPred: update on drug classification and target prediction","volume":"42","author":"Nickel","year":"2014","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib24","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky1151","article-title":"OMIM.org: leveraging knowledge across phenotype-gene relationships","volume":"47","author":"Amberger","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad751","article-title":"TTD: therapeutic target database describing target druggability information","volume":"52","author":"Zhou","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00714_bib28","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00714_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2003-4-5-p3","article-title":"DAVID: database for annotation, visualization, and integrated discovery","volume":"4","author":"Dennis","year":"2003","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00714_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"D1","key":"10.1016\/j.neurot.2025.e00714_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: new data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2025.e00714_bib32","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein data bank (PDB): the single global macromolecular structure archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00714_bib33","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","article-title":"Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations","volume":"81","author":"L\u00e4hteenvuo","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2024.03.014","article-title":"Muscarinic receptor activators as novel treatments for schizophrenia","volume":"96","author":"Paul","year":"2024","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23082087","article-title":"Current concepts and treatments of schizophrenia","volume":"23","author":"St\u0119pnicki","year":"2018","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00714_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/1044-7431(92)90030-6","article-title":"Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action","volume":"3","author":"Deutch","year":"1992","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.neurot.2025.e00714_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","article-title":"In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M(1) receptor, and xanomeline, an agonist of muscarinic M(1)\/M(4) receptor","volume":"414","author":"Mandai","year":"2019","journal-title":"Rodents Neuroscience"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0006-3223(00)01017-9","article-title":"The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex","volume":"49","author":"Perry","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00714_bib39","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-3565(25)23800-9","article-title":"Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity","volume":"271","author":"Robertson","year":"1994","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00714_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpsychires.2013.09.017","article-title":"Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-na\u00efve first-episode schizophrenia patients","volume":"48","author":"Gass\u00f3","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00714_bib41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10715762.2019.1572889","article-title":"Antipsychotic drugs scavenge radiation-induced hydroxyl radicals and intracellular ROS formation, and protect apoptosis in human lymphoma U937 cells","volume":"53","author":"Zhao","year":"2019","journal-title":"Free Radic Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00714_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033598","article-title":"Genome-wide association study of treatment refractory schizophrenia in han Chinese","volume":"7","author":"Liou","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00714_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro","volume":"450","author":"S\u00e1rv\u00e1ri","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00714_bib44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.neurot.2025.e00714_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113717","article-title":"Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug na\u00efve first-episode schizophrenia","volume":"297","author":"Chen","year":"2021","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neurot.2025.e00714_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112731","article-title":"The association between serum insulin-like growth factor 1 and cognitive impairments in patients with schizophrenia","volume":"285","author":"Chao","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.neurot.2025.e00714_bib47","article-title":"Insulin-like growth factor-1 and cognitive health: exploring cellular, preclinical, and clinical dimensions","volume":"76","author":"Hayes","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.neurot.2025.e00714_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpsychires.2016.07.018","article-title":"Decreased VEGFR2 expression and increased phosphorylated Akt1 in the prefrontal cortex of individuals with schizophrenia","volume":"82","author":"Hino","year":"2016","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00714_bib49","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2017.06.108","article-title":"Overexpression cdc42 attenuates isoflurane-induced neurotoxicity in developmental brain of rats","volume":"490","author":"Fang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00714_bib50","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.biopsych.2015.03.030","article-title":"Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia","volume":"78","author":"Datta","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00714_bib51","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0269881106062025","article-title":"Selective increases in the cytokine, TNFalpha, in the prefrontal cortex of PCP-treated rats and human schizophrenic subjects: influence of antipsychotic drugs","volume":"20","author":"Paterson","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neurot.2025.e00714_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pnpbp.2011.12.002","article-title":"Neuroinflammation in schizophrenia especially focused on the role of microglia","volume":"42","author":"Monji","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00714_bib54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"issue":"1-3","key":"10.1016\/j.neurot.2025.e00714_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr Res"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00714_bib56","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/febs.13627","article-title":"NFKB1: a suppressor of inflammation, ageing and cancer","volume":"283","author":"Cartwright","year":"2016","journal-title":"FEBS J"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00714_bib57","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00213-021-05824-9","article-title":"Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?","volume":"238","author":"Zhao","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00714_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41537-024-00504-x","article-title":"Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking","volume":"10","author":"Li","year":"2024","journal-title":"Schizophrenia (Heidelb)"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00714_bib59","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.pharep.2018.05.005","article-title":"Involvement of vascular endothelial growth factor (VEGF) and mitogen-activated protein kinases (MAPK) in the mechanism of neuroleptic drugs","volume":"70","author":"J\u00f3\u017awiak-B\u0119benista","year":"2018","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00714_bib60","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1038\/s41467-024-50925-6","article-title":"Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"issue":"1-3","key":"10.1016\/j.neurot.2025.e00714_bib61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2013.10.019","article-title":"Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway","volume":"151","author":"Dimitrov","year":"2013","journal-title":"Schizophr Res"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00714_bib62","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1532-5415.2010.02988.x","article-title":"Trospium chloride is undetectable in the older human central nervous system","volume":"58","author":"Staskin","year":"2010","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00714_bib63","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder","volume":"64","author":"Staskin","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00714_bib64","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/14656566.7.10.1373","article-title":"Trospium chloride: the European experience","volume":"7","author":"Madersbacher","year":"2006","journal-title":"Expet Opin Pharmacother"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925001928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:47:27Z","timestamp":1778831247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925001928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925001928"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00714","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shared and unique therapeutic targets of KarXT and clozapine for schizophrenia treatment revealed by network pharmacology and molecular docking analyses: Implications for differential clinical responses","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00714"}}